Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine.
Piotr Rzymski,Monika Pazgan-Simon,Krzysztof Simon,Tadeusz Wojciech Łapiński,Dorota Zarębska-Michaluk,Barbara Szczepańska,Michał Chojnicki,Iwona Mozer-Lisewska,Robert Flisiak +8 more
TLDR
In this article, the authors retrospectively analyzed the 92 cases of patients who were hospitalized between 27 December 2020 and 31 May 2021 in four Polish healthcare units due to COVID-19, and who have previously received the vaccine.About:
This article is published in Vaccine.The article was published on 2021-07-13 and is currently open access. It has received 20 citations till now. The article focuses on the topics: Vaccine failure & Vaccination.read more
Citations
More filters
Journal ArticleDOI
Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland
TL;DR: In this paper, a cross-sectional online study of adult Poles was conducted to assess the attitude of individuals who completed the current vaccination regime toward a potential booster dose of the COVID-19 vaccine and identify potential factors that may influence it.
Journal ArticleDOI
COVID-19 Vaccine Boosters: The Good, the Bad, and the Ugly
Piotr Rzymski,Piotr Rzymski,Carlos A. Camargo,Carlos A. Camargo,Andrzej M. Fal,Robert Flisiak,Willis Gwenzi,Roya Kelishadi,Roya Kelishadi,Alexander Leemans,Alexander Leemans,Juan J. Nieto,Juan J. Nieto,Ahmet Ozen,Ahmet Ozen,Matjaž Perc,Matjaž Perc,Matjaž Perc,Barbara Poniedziałek,Barbara Poniedziałek,Constantine Sedikides,Constantine Sedikides,Frank W. Sellke,Frank W. Sellke,Emilia C. Skirmuntt,Anzhela Stashchak,Anzhela Stashchak,Nima Rezaei,Nima Rezaei +28 more
TL;DR: In this paper, the authors discuss whether the administration of booster doses of COVID-19 vaccines is urgently needed to control the SARS-CoV-2 pandemic, concluding that, at present, optimizing the immunity level of wealthy populations cannot come at the expense of low-income regions that suffer from vaccine unavailability.
Journal ArticleDOI
COVID-19 Breakthrough Infections and Transmission Risk: Real-World Data Analyses from Germany’s Largest Public Health Department (Cologne)
Lea Hsu,Barbara Grüne,Michael Buess,Christine Joisten,Jan Klobucnik,Johannes Nießen,David Patten,Anna Wolff,Gerhard Andreas Wiesmüller,Annelene Kossow,Julia Hurraß +10 more
TL;DR: In this paper, the authors calculated the real-world transmission risk from fully vaccinated patients (vaccination group, VG) to their close contacts (CP) compared with the risk from unvaccinated reference persons matched according to age, sex, and virus type.
Journal ArticleDOI
The association of airborne particulate matter and benzo[a]pyrene with the clinical course of COVID-19 in patients hospitalized in Poland
Piotr Rzymski,Barbara Poniedziałek,Joanna Rosińska,Magdalena Rogalska,Dorota Zarębska-Michaluk,Marta Rorat,Anna Moniuszko-Malinowska,Beata Lorenc,Dorota Kozielewicz,Anna Piekarska,Katarzyna Sikorska,Anna Dworzańska,Beata Bolewska,Grzegorz Angielski,Justyna D. Kowalska,Regina Beata Podlasin,Barbara Oczko-Grzesik,Włodzimierz Mazur,Aleksandra Szymczak,Robert Flisiak +19 more
TL;DR: In this article , the authors explored the relationship between symptomatology, clinical course, and inflammation markers of adult patients with coronavirus disease 2019 (COVID-19) hospitalized in Poland (n = 4432) and air pollution levels, i.e., mean 24 h and max 24 h level of benzo(a)pyrene (B(a)/P) and particulate matter <10 μm (PM10) and <2.5 μm(PM2.
Journal ArticleDOI
COVID-19 Vaccination and Rates of Infections, Hospitalizations, ICU Admissions, and Deaths in the European Economic Area during Autumn 2021 Wave of SARS-CoV-2
Dominika Sikora,Piotr Rzymski +1 more
TL;DR: The vaccination of unvaccinated individuals should remain the primary strategy to decrease the hospital overloads, severe consequences of COVID-19, and deaths during the autumn 2021 SARS-CoV-2 wave.
References
More filters
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application.
Stephen A. Lauer,Kyra H. Grantz,Qifang Bi,Forrest K. Jones,Qulu Zheng,Hannah R. Meredith,Andrew S. Azman,Nicholas G. Reich,Justin Lessler +8 more
TL;DR: The results support current proposals for the length of quarantine or active monitoring of persons potentially exposed to SARS-CoV-2, although longer monitoring periods might be justified in extreme cases.
Journal ArticleDOI
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Merryn Voysey,Clemens Sac.,Shabir A. Madhi,Lily Yin Weckx,P M Folegatti,Parvinder K. Aley,Brian Angus,Vicky L. Baillie,Shaun Barnabas,Q E Bhorat,S Bibi,Carmen Briner,P Cicconi,Andrea M. Collins,R Colin-Jones,Clare L. Cutland,Thomas C. Darton,Keertan Dheda,Duncan Cja.,Emary Krw.,Katie J. Ewer,Lee Fairlie,Saul N. Faust,Shuo Feng,Daniela M. Ferreira,Adam Finn,Anna Goodman,Catherine M. Green,Christopher A Green,Paul T. Heath,Christopher Hill,Helen Hill,Ian Hirsch,Hodgson Shc.,Allen Izu,S Jackson,D Jenkin,Joe Ccd.,S Kerridge,Anthonet Koen,Gaurav Kwatra,Rajeka Lazarus,Alison M. Lawrie,A Lelliott,Vincenzo Libri,Patrick J. Lillie,R Mallory,Mendes Ava.,Eveline Pipolo Milan,Angela M. Minassian,Alastair McGregor,Hazel Morrison,Y Mujadidi,Amit J Nana,P J O’Reilly,S D Padayachee,A Pittella,E Plested,Katrina M Pollock,M N Ramasamy,S Rhead,Alexandre Vargas Schwarzbold,Nisha Singh,Andrew Smith,R Song,Matthew D. Snape,Eduardo Sprinz,Rebecca K. Sutherland,R Tarrant,E. Thomson,M E Török,Mark Toshner,Turner Dpj.,Johan Vekemans,Tonya Villafana,Watson Mee.,C J Williams,Alexander D. Douglas,Hill Avs.,Teresa Lambe,Sarah C. Gilbert,Andrew J. Pollard +81 more
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
TL;DR: The mRNA-1273 vaccine as discussed by the authors is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19.
Journal ArticleDOI
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
Edward E. Walsh,Robert W. Frenck,Ann R. Falsey,Ann R. Falsey,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,Kathleen M. Neuzil,Mark J. Mulligan,Ruth Bailey,Kena A. Swanson,Ping Li,Kenneth Koury,Warren Kalina,David A. Cooper,Camila R. Fontes-Garfias,Pei Yong Shi,Özlem Türeci,Tompkins Kristin Rachael,Kirsten E. Lyke,Vanessa Raabe,Philip R. Dormitzer,Kathrin U. Jansen,Ugur Sahin,William C. Gruber +25 more
TL;DR: The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults support the selection of BNT162b2 for advancement to a pivotal phase 2–3 safety and efficacy evaluation.
Related Papers (5)
SARS-CoV-2 vaccine effectiveness in immunosuppressed kidney transplant recipients
Hiam Chemaitelly,Hiam Chemaitelly,Sawsan AlMukdad,Sawsan AlMukdad,Jobin Paravila Joy,Houssein H. Ayoub,Hadi M. Yassine,Hadi M. Yassine,Fatiha M. Benslimane,Fatiha M. Benslimane,Hebah A. Al Khatib,Hebah A. Al Khatib,Patrick Tang,Mohammad Rubayet Hasan,Peter Coyle,Peter Coyle,Peter Coyle,Zaina Al Kanaani,Einas Al Kuwari,Andrew Jeremijenko,Anvar Hassan Kaleeckal,Ali Nizar Latif,Riyazuddin Mohammad Shaik,Hanan F. Abdul Rahim,Gheyath K. Nasrallah,Gheyath K. Nasrallah,Mohamed Ghaith Al Kuwari,Adeel A. Butt,Adeel A. Butt,Hamad Eid Al Romaihi,Mohamed H. Al-Thani,Mohamad M. Alkadi,Omar Ali,Muna Almaslamani,Roberto Bertollini,Hassan Al Malki,Yousuf Almaslamani,Laith J. Abu-Raddad,Abdullatif Al Khal +38 more